My career choice, statistics, should never have been a
surprise. I have always kept track of and tried to learn from details. While
the pembrolizumab infusion was completing this morning, the nurse asked how
many additional treatments are planned. We explained that there is no really
good long-term data on pembrolizumab in bladder cancer, but we are hoping that
updated data from the pivotal trial that led to the drug’s approval in this
indication will be presented at the upcoming American Society for Clinical
Oncology Genitourinary Cancers Symposium in San Francisco in mid-February. This
led the nurse to suggest that we might just continue until the drug stops
working. I do not think she really meant for that to come out as badly as it
sounded, but I quickly pointed out that I certainly hope we will not get to
that point.
I found myself coming home from treatment and wondering just
how many pembrolizumab infusions I have had so far. I was able to easily reconstruct
this from my Google calendar and confirm with my on-line medical record from
MSKCC, and the answer is 12 – one dozen treatments.
|
Dose #
|
Day
|
Date
|
|
1
|
Friday
|
23
February
|
|
2
|
Friday
|
16
March
|
|
3
|
Thursday
|
05
April
|
|
4
|
Friday
|
27
April
|
|
5
|
Tuesday
|
22
May
|
|
6
|
Monday
|
11
June
|
|
7
|
Friday
|
06
July
|
|
8
|
Friday
|
27
July
|
|
9
|
Friday
|
17
August
|
|
10
|
Friday
|
07
September
|
|
11
|
Friday
|
28
September
|
|
12
|
Wednesday
|
24
October
|
No one knows just how many treatments are “enough.” We did
not see Dr. Iyer (oncologist) today but I believe this topic is one he intends
to discuss with us over the next few months.
Meanwhile, I need to get some rest now. The treatment does
leave me tired, but that is a relatively small price to pay as long as it
works!
Love,
Rebecca
No comments:
Post a Comment